Diabetes mellitus (DM) contributes to the exacerbation of left ventricle (LV) dysfunction after myocardial infarction (MI). Activation of ERK5, an atypical mitogen activated protein kinase with transcriptional activity, inhibits apoptosis and LV dysfunction after doxorubicin treatment. SUMOylation has been proposed as a negative regulator of various transcription factors. In the current study, we investigated the role of ERK5-SUMOylation in ERK5 transcriptional activity as well as on DM-mediated exacerbation of LV dysfunction and apoptosis after MI. ERK5 wild-type transcriptional activity was inhibited by Ubc9 (SUMO E2 conjugase) or PIAS1 (E3 ligase), but not in the ERK5-SUMOylation-site defective mutant (K6R/K22R). H 2 O 2 and high glucose, 2 well-known mediators of diabetes, induced ERK5-SUMOylation, and the K6R/K22R mutant, dominant negative form of Ubc9, and siRNA-PIAS1 reversed H 2 O 2 -mediated reduction of ERK5 transcriptional activity in cardiomyocytes, indicating the presence of SUMOylationdependent ERK5 transcriptional repression. Constitutively active form of MEK5␣ (CA-MEK5␣) inhibited ERK5-SUMOylation independent of kinase activity, but dependent on MEK5-ERK5 association. To investigate the pathological role of ERK5-SUMOylation in DM mice after MI, we used cardiac specific CA-MEK5␣ transgenic mice (CA-MEK5␣-Tg). MI was induced in streptozotocin (STZ)-injected (DMϩMI group) or vehicle-injected mice (MI group) by ligating the left coronary artery. The ERK5-SUMOylation was increased in the DMϩMI, but not in the MI group. ERK5-SUMOylation, the exacerbation of LV dysfunction, and the number of TUNEL-positive cells in DMϩMI was significantly inhibited in CA-MEK5␣-Tg mice. Of note, we could not detect any difference of cardiac function after MI in non-diabetic CA-MEK5␣-Tg and non-transgenic littermate control mice. These results demonstrated that ERK5 transcriptional activity is subject to downregulation by diabetes-dependent SUMOylation, which resulted in a proapoptotic condition contributing to poor post-MI LV function.
D iabetes is an independent risk factor for both mortality and morbidity after myocardial infarction (MI). 1,2 A number of clinical studies have shown that the post-MI left ventricular (LV) function is significantly worse in diabetic compared with nondiabetic patients. 3, 4 However, what is lacking is a plausible relationship between diabetes and any of the known regulators of myocyte apoptosis known to play a significant role in the post-MI cardiac dysfunction. Previously, we have demonstrated that downregulation of phosphodiesterase 3A (PDE3A) is associated with apoptosis and induction of inducible cAMP early repressor (ICER), a proapoptotic transcriptional repressor, providing a mechanistic framework for how angiotensin II (Ang II) regulates myocyte apoptosis. 5, 6 Sustained elevation of ICER favors apoptosis through inhibition of cAMP response element binding protein (CREB)-mediated transcription and downregulation of Bcl-2. Interactions between PDE3A and ICER constitute an autoregulatory positive feedback loop (PDE3A-ICER feedback loop) likely to determine the fate of injured myocytes. ERK5, an atypical mitogen activated protein kinase with transcriptional activity, negatively regulates the executor PDE3A-ICER feedback loop and subsequent apoptosis. 7 Our recent data indicated that ERK5 transcriptional activity itself is subjected to downregulation by reactive oxygen species (ROS) and advanced glycogen endproducts (AGE)-dependent small ubiquitin-related modification (SUMO), and inhibits KLF2 and eNOS expression in endothelial cells. 8 ERK5-SUMOylation at the NH 2 -terminal region (K6 and K22) significantly inhibits COOH-terminal ERK5 transcriptional activity. 8 Posttranslational modification by SUMO commonly regulates the assembly and disassembly of protein complexes, protein localization, stability, and function. 9 SUMOylation is known to be highly substoichiometric because it often generates intermediates that result in new protein interactions or conformational states that persist even after SUMO removal. 9 In the current study, we showed that ERK5 is 1 of the major targets of SUMOylation in diabetic hearts. We found that SUMOylation-dependent ERK5 transcriptional repression induced by ROS and high glucose. Constitutively active form of MEK5␣ (CA-MEK5␣) inhibited ERK5-SUMOylation independent of its kinase activity but dependent on MEK5-ERK5 association. Diabetic hearts demonstrating exacerbation of LV dysfunction after myocardial infarction (MI) were accompanied by enhanced ERK5-SUMOylation. The inhibition of ERK5-SUMOylation by CA-MEK5␣ significantly improved the cardiac function after MI in diabetic mice but not in nondiabetic mice. These data suggested the importance of ERK5-SUMOylation on ROSmediated ERK5 transcriptional repression, which contributes to poor cardiac function after MI in diabetes.
Materials and Methods
Details on reagents, antibodies, plasmid and adenovirus vectors construction, cell culture, mammalian 1-hybrid analysis and transfection of cells, immunoprecipitation (SUMOylation assay) and Western blot analysis, transfection of the PIAS1 siRNA, analysis of apoptosis, animal models, streptozotocin (STZ) injections, coronary ligation surgery, echocardiographic analysis and in vivo hemodynamic measurements, and statistical analysis are also provided in the online Data Supplement (available online at http://circres. ahajournals.org).
Results

Streptozotocin (STZ)-Induced Hyperglycemia Exacerbates LV Dysfunction and Failure After an Experimental MI
Diabetes adversely affects LV dysfunction after MI and leads to a higher incidence of heart failure, but the exact mechanism of diabetes-mediated exacerbation of LV dysfunction remains largely unknown. First, we established a diabetic mouse model in our laboratory and demonstrated the development of heart failure after MI as previously described. 10 Figure 1 . STZ-induced hyperglycemia exacerbates LV dysfunction and mortality after MI. A, Random blood sugar (BS) and body weight 1 week after injection of STZ (DM) or vehicle (control) in sham or coronary ligation (MI) groups. B, Kaplan-Meier survival analysis. Survival rate in diabetes mellitus (DM) ϩ myocardial infarction (MI) (nϭ35) and MI (nϭ25) mice were plotted. Overall survival was significantly lower in DMϩMI compared with MI mice. C, LV weight/tibial length (TL) and lung weight/TL 1 week after sham or coronary ligation (MI) in STZ-(DM) or vehicle (control)-treated groups. D and E, Echocardiogram obtained from control (sham and no STZ), DM (sham and STZ), MI (coronary ligation and no STZ), and DMϩMI (coronary ligation and STZ) mouse 1 week after surgery. Dd indicates end-diastolic diameter; Ds, end-systolic diameter; FS, fractional shortening; n, number of the animals.
Four groups of mice were studied. Diabetes mellitus (DM) was induced in male FVB mice (5 to 8 weeks old and 25 to 35 g body weight, The Jackson Laboratory, Bar Harbor, ME) by intraperitoneal injection of STZ (200 mg/kg body weight). 10, 11 Tail vein blood glucose samples were measured 6 days after injection to ensure induction of hyperglycemia. As a control, vehicle (0.1 mol/L citrate buffer, pH 4.5) was injected in another group of mice. At 7 days after injection, MI was induced in STZ-injected (DMϩMI group) or vehicleinjected mice (MI group) by ligating the left coronary artery. 10, 12 We have carefully characterized the fasting glucose level after different doses of intraperitoneal injection of STZ in FVB mice and found that one injection of 200 mg/kg body weight STZ resulted in fasting blood glucose (FBG) of around 200 mg/dL at 1 week after injection. Because mice with extremely high glucose level (Ͼ 400 mg/dL) did not tolerate the coronary ligation surgery well, we chose a STZ dose that resulted in this moderately high FBG as the diabetic mice model for our study. A sham operation without ligating the coronary artery was also performed in additional groups of STZ-injected (DM group) and salineinjected mice (control group). All 4 groups of mice (control, DM, MI, and DMϩMI) were followed up for another 1 week (1-week post-MI study). STZ treatment significantly increased random blood sugar (BS) levels 2 weeks after injection ( Figure 1A , left panel). Of note, we did not observe any significant body weight difference between the MI and DMϩMI groups at 1 week after injection and at the time of surgery ( Figure 1A , right panel), and at 1 week after surgery (supplemental Table I ). Survival at 1 week after MI was significantly lower in the DMϩMI versus MI group ( Figure 1B) . were immunoprecipitated with anti-ERK5 antibody, and Western blot analysis was performed with anti-SUMO2/3 antibody (top). A significant decrease in ERK5 phosphorylation was observed in both MI and DMϩMI groups (2nd from top) but with no difference in the amount of total ERK5 (3nd from top). Immunoblot with SUMO2/3 antibody (4th from top) and Ubc9 antibody (bottom) confirmed no significant differences in the general SUMOylation of proteins and the Ubc9 expression between samples. B, Heart samples from control and DMϩMI mice without or with preoperative insulin treatment subjected to IP with ERK5 antibody and IB with anti-SUMO2/3 antibody. The preoperative insulin treatment decreased ERK5-SUMOylation (arrow) in the DMϩMI group. Cardiomyocytes were treated with H 2 O 2 (C, D) or high glucose and mannitol (E) and probed for SUMOylated ERK5. C, Cells treated for the indicated time were lysed and immunoprecipitated using anti-ERK5 antibody then blotted with anti-SUMO2/3 (top) and ERK5 (bottom) antibodies. D, H 2 O 2 -mediated ERK5-SUMOylation was measured at one hour at the indicated concentration of H 2 O 2 (top). No significant difference of ERK5 expression among the samples was observed (bottom). E, After treatment of cardiomyocytes with high glucose or mannitol, cells were lysed and immunoprecipitated with anti-ERK5 antibody and Western blot analysis was performed with anti-SUMO2/3 antibody (top). No significant difference of free forms of SUMO2/3 (middle) and Ubc9 (bottom) expression among the samples was observed. Data are representative of results from experiments performed on at least 3 separate occasions.
We could not detect any difference in LV weight/tibial length (TL) between the MI and DMϩMI groups. But lung weight/TL was increased in the MI group, which was significantly exacerbated in the DMϩMI group ( Figure 1C ), suggesting a more severe congestive heart failure in the DMϩMI group than MI group. Echocardiography 1 week after ligation showed LV dilatation and dysfunction in the MI group but with both measures exaggerated in the DMϩMI group ( Figure 1D and 1E; supplemental Table I ).
ERK5-SUMOylation in DM؉MI Model
Recently, we have reported the importance of ERK5-SUMOylation on regulating its transcriptional activity. 8 H 2 O 2 and advanced glycation end products (AGE), 2 well-known mediators of diabetes, negatively regulated ERK5 transcriptional activity via ERK5-SUMOylation in endothelial cells. Because ERK5 demonstrates a cardio-protective effect, 7 we investigated the effect of STZ-mediated hyperglycemia and MI on the ERK5-SUMOylation. As shown in Figure 2 , we found a slight increase of ERK5-SUMOylation in both the DM (with sham operation) and MI (without STZ treatment) groups. In contrast, the ERK5-SUMOylation was signifi-cantly exaggerated in the DMϩMI group. These data suggested the possible role of ERK5-SUMOylation on the exaggerated LV dysfunction and development of heart failure after MI in DM mice. In contrast, a reduction of ERK5 phosphorylation was observed in both MI and DMϩMI groups compared with non-MI control and DM groups. No significant difference in ERK5 phosphorylation was observed in MI versus DMϩMI groups, suggesting that ERK5 phosphorylation and its subsequent kinase activation may not be involved in the exaggerated LV dysfunction after MI in DM mice.
We investigated the possible cardio-toxic effect of STZ, as opposed to hyperglycemia, by administering insulin (60 U/kg subcutaneous b.i.d. NPH human insulin [Humulin N; Eli Lilly]) 1 to 2 days before the coronary ligation surgery to normalize the FBG and determined infarct size, cardiac function, and the biochemical markers such as ERK5-SUMOylation after MI as previously described. 13 We demonstrated that preoperative insulin treatment of STZ-injected mice decreased the FBG to 157.6Ϯ49.5 mg/dL. Such preoperative insulin-treatment did not result in significant differences in basal cardiac function from nondiabetic MI control (data not shown). In addition, we could not detect any increase in ERK5-SUMOylation after insulin-treatment, which was observed in the hyperglycemic DMϩMI mice ( Figure 2B ). Therefore, we concluded that the exacerbation of cardiac damage and ERK5-SUMOylation in DMϩMI model was attributable to hyperglycemia and not to STZ toxicity.
One of the major concerns of this study is whether the observed differences between the groups can be accounted for by metabolic perturbations (particularly malnutrition and weight loss in the diabetic animals), or by the direct effects of STZ on the myocardium. We carefully examined this issue and found that both MI alone and DMϩMI animals had equally low body weights, but DMϩMI mice showed greater cardiac damage ( Figure 1A ; supplemental Table I ).
H 2 O 2 Inhibited ERK5 Transcriptional Activity and Induced Apoptosis via ERK5-SUMOylation
Because we found ERK5-SUMOylation in the DMϩMI group, and ERK5-SUMOylation could decrease ERK5 transcriptional activity and possibly its cardio-protective effect, we investigated whether H 2 O 2 and high glucose can induce endogenous ERK5-SUMOylation. As shown in Figure 2C and 2D, H 2 O 2 significantly increased ERK5-SUMOylation in a time-and dose-dependent manner. High glucose, but not mannitol (20 mmol/L) as a control, also increased ERK5-SUMOylation ( Figure 2E ). Previously, we reported that H 2 O 2 and advanced glycation end products (AGE) inhibited ERK5 transcriptional activity via ERK5-SUMOylation in endothelial cells. 8 Because we found that H 2 O 2 and high glucose could induce ERK5-SUMOylation in cardiomyocytes ( Figure  2C Next, we compared the H 2 O 2 (30 mol/L)-induced reduction of transcriptional activity in the wild-type and SUMOylation sites-mutant (K6R/K22R) ERK5. As shown in Figure 3B , H 2 O 2 -induced reduction of ERK5 transcriptional activity was significantly less in the ERK5-K6R/ K22R mutant. To further confirm the involvement of ERK5-SUMOylation in transcriptional regulation, we tested whether deletion of PIAS1 using PIAS1 siRNA could inhibit the H 2 O 2 -mediated reduction of ERK5 transcriptional activity. PIAS1 siRNA inhibited PIAS1 expression and H 2 O 2 -mediated ERK5-SUMOylation in cardiomyocytes ( Figure 3C ). Furthermore, PIAS1 siRNA significantly prevented H 2 O 2 -mediated reduction of ERK5 transcriptional activity ( Figure 3D ). Taken together, these data strongly suggested the critical role of ERK5-SUMOylation in H 2 O 2 -mediated reduction of ERK5 transcriptional activity.
We have reported previously the importance of ERK5 in the regulation of cardiomyocyte apoptosis. 7 Therefore, we investigated whether ERK5-SUMOylation was involved in the H 2 O 2 -mediated apoptosis. As shown in Figure 4 , in this model the deletion of PIAS1 significantly inhibited H 2 O 2mediated apoptosis. To further support the critical role of ERK5-SUMOylation in regulating cardiomyocyte apoptosis, we generated 2 adenovirus vectors expressing the ERK5 wild-type and ERK5 K6R/K22R mutant. Sixteen hours after transduction with adenovirus vector containing Xpress tagged-ERK5 wild-type (Ad-ERK5-WT) or ERK5 K6R/ K22R mutant (Ad-ERK5 K6R/K22R), cardiomyocytes were treated with H 2 O 2 (100 mol/L) for 24 hours, and apoptosis was measured by TUNEL staining. We found that expression of ERK5-SUMOylation site-mutant significantly inhibited H 2 O 2 -induced apoptosis ( Figure 4C) . No difference in the amount of ERK5 wild-type and K6R/K22R mutant expression was confirmed in samples by immunoblotting with anti-Xpress antibody ( Figure 4C ). Of note, we needed to increase the concentration of H 2 O 2 from 30 mol/L to 100 mol/L in this set of experiments because we could not detect significant increase of TUNEL positive cells in Ad-ERK5 WT tranduced cells with 30 mol/L H 2 O 2 treatment, probably because of the protective effect of ERK5 wild-type overexpression.
Interaction of MEK5␣ With ERK5 Inhibits ERK5-SUMOylation but not MEK5␣-Mediated ERK5 Kinase Activation
It has been reported that ERK5 activation inhibits MEF2-SUMOylation via MEF2-Ser179 phosphorylation and increases MEF2 transcriptional activity. 14 Therefore, we investigated whether MEK5 activation induced by CA-MEK5␣ can similarly inhibit Ubc9 and SUMO3-mediated ERK5-SUMOylation. As shown in Figure 5A , CA-MEK5␣ significantly inhibited Ubc9 and SUMO3-mediated ERK5-SUMOylation (lanes 1 through  3) . These data suggested that CA-MEK5␣ could potentially transcriptionally activate ERK5 via inhibiting SUMOylation and Figure 5 . Association of MEK5 with ERK5, but not ERK5 kinase activation and phosphorylation, inhibits ERK5-SUMOylation. A, CA-MEK5␣-mediated reduction of ERK5-SUMOylation was observed in both ERK5 wild type and kinase dead TEY motif mutant (ERK5-AEF). CHO cells were cotransfected with HA-SUMO3, Ubc9, DN-Ubc9, and Xp-tagged ERK5 (WT or ERK5-AEF kinase dead mutant) with CA-MEK5␣ or control cDNA as indicated and ERK5-SUMOylation assay performed as described above. No difference in the amount of ERK5 wild type and mutants (2nd from the top), CA-MEK5␣ (3rd from top), or Ubc9 (4th from top) was observed in samples by Western blot analysis. The expression of free forms of SUMO2/3 and SUMO conjugated 30 to 280 kDa proteins were detected by immunoblotting with anti-SUMO2/3 antibody (bottom). B, Both MEK5 binding site truncated mutants of ERK5 (ERK5-⌬aa72-139, and ERK5-⌬aa90 -130) did not associate with MEK5␣. Cells were cotransfected with Xp-tagged ERK5 (WT or ERK5-⌬aa72-139, and ERK5-⌬aa90 -130) with HA tagged CA-MEK5␣ or control cDNA as indicated. After 24 hours of transfection, whole cell extract was immunoprecipitated with anti-HA antibody and Western blot analysis was performed with anti-HA (upper) or ERK5 (lower) antibody. No difference in the amount of ERK5 wild type and mutants or HA-CA-MEK5␣ was observed in samples by Western blot analysis. C, Both MEK5 binding site truncated mutants of ERK5 (ERK5-⌬aa72-139, and ERK5-⌬aa90 -130) inhibited CA-MEK5␣-mediated reduction of ERK5-SUMOylation. Cells were cotransfected with HA-SUMO3, Ubc9, DN-Ubc9, and Xp-tagged ERK5 (WT or ERK5-⌬aa72-139, and ERK5-⌬aa90 -130) with CA-MEK5␣ or control cDNA as indicated and performed ERK5-SUMOylation assay as described above. No difference in the amount of ERK5 wild type and mutants (2nd and 3rd from the top), or CA-MEK5␣ (4th from the top) was observed in samples by Western blot analysis. *Activated (phosphorylated) form of ERK5 showed band shift as previously described 19 provides a novel mechanism of MEK5␣ activation of ERK5 via inhibition of ERK5-SUMOylation.
To determine the effect of MEK5␣-mediated ERK5 phosphorylation on ERK5-SUMOylation, we mutated the TEY phosphorylation motif of ERK5, which is critical for ERK5 kinase activation, 15 and investigated whether these mutations can affect the CA-MEK5␣-mediated inhibition of ERK5-SUMOylation. As shown in Figure 5A (lanes 4 through 6) , although it is well known that the ERK5 kinase cannot be activated without the TEY motif phosphorylation, 15 mutation of this motif had no effect on CA-MEK5␣-mediated reduction of ERK5-SUMOylation. This suggested that both ERK5 kinase activation and TEY motif phosphorylation were not involved in the CA-MEK5␣-induced inhibition of ERK5-SUMOylation. Of note, despite the presence of CA-MEK5␣induced inhibition of ERK5-SUMOylation, no significant difference in the SUMO conjugated 75-and 110-kDa proteins and other SUMO conjugated proteins between 30 to 280 kDa with or without CA-MEK5␣ transfection was noted. These data suggested that CA-MEK5␣ may have a unique regulatory role in ERK5-SUMOylation distinct from the general SUMOylation process induced by Ubc9/SUMO3.
Residues 78 to 139 of ERK5 constitutes the MEK5␣binding domain. 16 To investigate the contribution of MEK5-ERK5 association on CA-MEK5␣-induced inhibition of ERK5-SUMOylation, we generated 2 deletion mutants of the MEK5␣-ERK5 association site, ⌬72 to 139 and ⌬90 to 130, with respective deletions of the numbered residues. Coimmunoprecipitation studies confirmed the lack of association between these ⌬-mutants and MEK5␣ ( Figure 5B ). Cotransfection of HA-SUMO3 and Ubc9 induced ERK5-SUMOylation, which was inhibited by CA-MEK5␣ induction ( Figure 5C, lanes 1 through 3) . As shown in Figure 5C (lanes  4 through 7) , both MEK5 binding site ⌬-mutants were SUMOylated, but CA-MEK5␣ no longer substantially inhibited ERK5-SUMOylation compared with WT. These data indicate the critical role of ERK5-MEK5 association, but not ERK5 kinase activation and TEY motif phosphorylation, on CA-MEK5␣-mediated inhibition of ERK5-SUMOylation.
ERK5-SUMOylation, PDE3A-ICER Feedback Loop, and Apoptosis in DM؉MI Mice Was Significantly Inhibited in CA-MEK5␣-Tg Mice
As shown in Figure 2 , we found that ERK5-SUMOylation was significantly increased in DMϩMI mice heart. However, the involvement of ERK5-SUMOylation on diabetesmediated exacerbation of LV dysfunction after MI remains unclear. Because CA-MEK5␣-mediated MEK5-ERK5 association inhibited ERK5-SUMOylation in vitro we investigated whether DM-mediated ERK5-SUMOylation might be inhibited in cardiac specific CA-MEK5␣-Tg mice. As shown in Figure 6A (top panel) , ERK5-SUMOylation was significantly increased at 1 week after MI in diabetic nontransgenic littermate control (NLC) mice. In contrast, we did not find any significant MI-induced increase in ERK5-SUMOylation in diabetic CA-MEK5␣-Tg mice. Previously, we have reported on the critical role of ERK5 activation in regulating the PDE3A/ICER feedback loop in a heart failure model. 7 Because we found that ERK5-SUMOylation inhibited ERK5 transcriptional activity, we determined whether the induction of PDE3A/ICER feedback loop in DMϩMI mice can also be inhibited in the CA-MEK5␣-Tg mice. As shown in Figure  6C , we found a reduction of PDE3A and ICER induction at 1 week after MI in diabetic NLC mice but significantly inhibited in CA-MEK5␣-Tg mice. ERK5 phosphorylation was decreased in diabetic NLC mice after MI as we have shown in Figure 2A , but was recovered in CA-MEK5␣-Tg mice (Figure 6A, 2nd panel from the top) . No significant differences in Akt and activation between NLC and CA-MEK5␣-Tg mice were observed in this model ( Figure 6B , top and 2nd from the top). In contrast to ERK5, we found that ERK1/2 phosphorylation was increased in both diabetic NLC and CA-MEK5␣-Tg mice after MI, which suggested the different regulatory mechanism of ERK1/2 compared with ERK5 after MI in DM mice ( Figure 6B, 3rd from the top and Apoptosis is believed to be important for the development of heart failure. 17 In NLC mice hearts 1 week after MI, the number of in situ TUNEL-positive cells increased to 0.32Ϯ0.12%, with a greater increase to 0.91Ϯ0.39% in the remote areas from the DMϩMI model ( Figure 7B ). We found significantly decreased TUNEL-positive cells in diabetic CA-MEK5␣-Tg mice compared with diabetic NLC mice at the same time point after MI ( Figure 7B ). These data support the antagonistic role of ERK5 activation in DMmediated exacerbation of cardiac apoptosis after MI.
Cardiac Dysfunction One Week After MI in DM, but not in Non-DM Mice, Was Rescued in CA-MEK5␣-Tg Mice
Because we found an inhibitory role for CA-MEK5␣ on ERK5-SUMOylation and subsequent PDE3A and the ICER feedback loop and apoptosis, we next investigated whether the inhibition of ERK5-SUMOylation by CA-MEK5␣ can prevent the exacerbation of LV dysfunction and heart failure after MI in DM mice in vivo. No survival difference was noted between NLC and CA-MEK5␣-Tg mice at the 1-week time point after MI in nondiabetic mice ( Figure 8A ). In contrast, in STZ-treated DM mice, the survival rate for CA-MEK5␣ was significantly higher than for NLC mice ( Figure 8B ). Random BS levels were elevated in both NLC and CA-MEK5␣-Tg mice 1 week after STZ injection and at the time of surgery, but we did not find any difference in the body weight among these groups ( Figure 8C ).
One week after coronary ligation, both LV weight/TL and lung weight/TL were increased in diabetic NLC mice. In CA-MEK5␣-Tg mice lung weight/TL was significantly decreased, consistent with the idea that MEK5␣ activation reduces cardiac dysfunction and heart failure after MI in diabetic mice ( Figure 8D ; supplemental Table I ). In NLC mice, echocardiographic analysis showed that both LVEDD and LVESD after MI in DM mice were greater than in sham, and FS% also significantly decreased in DMϩMI group ( Figure 8E; supplemental Table I ). Increased in LVEDD and LVESD and the reduction of FS% after MI in diabetic NLC mice were significantly prevented in CA-MEK5␣-Tg mice ( Figure 8E ). Of note, there was no significant difference in cardiac function (FS%) between NLC and CA-MEK5␣-Tg mice at the same time point after MI in nondiabetic mice ( Figure 8F ), confirming the unique role of MEK5␣ activation on DM-mediated exacerbation of LV dysfunction after MI. In agreement with echocardiographic data, we observed a significant decrease in developed pressure (DP) and dP/dt max in diabetic NLC mice after MI. In contrast, diabetic CA-MEK5␣-Tg mice showed significantly higher DP and dP/dt max ( Figure 8G ; supplemental Table II ). Thus physiological data also confirmed the critical role of MEK5 activation in ameliorating the exacerbation of cardiac dysfunction after MI by DM.
Discussion
In this study we found that ERK5-SUMOylation was significantly increased after MI in diabetic mice. Diabetic CA-MEK5␣-Tg mice demonstrated reduced ERK5-SUMOylation and improved LV function and lung weight/TL after MI in comparison to the NLC mice. These data strongly suggested that the activation of MEK5, which inhibited diabetesmediated ERK5-SUMOylation after MI, was cardioprotective against STZ-induced exacerbation of LV dysfunction after MI. Because both H 2 O 2 and high glucose increased ERK5-SUMOylation, it is most likely that ROS production Figure 7 . Apoptosis in the remodeling area was enhanced in DMϩMI group compared with MI alone group, which was significantly attenuated in CA-MEK5␣-Tg mice. TUNEL-positive cardiomyocytes were counted in the remodeling area of each animal. The animals were subjected to either MI or sham and allowed to survive for 1 week. TUNEL-positive myocytes were counted among more than 1000 to 4000 nuclei in the remodeling area of each animal. A, Representative pictures of TUNEL (top), 4Ј,6-diamidino-2-phenylindole (DAPI) (middle), and ␣-actinin (bottom) staining of the remote areas from NLC and CA-MEK5␣-Tg subjected to MI with or without diabetes as indicated. Note that there were significantly fewer TUNELpositive myocytes in the remote area after MI in diabetic CA-MEK5␣-Tg than in NLC mice. B, A bar graph summary of TUNEL-positive cells (%). Data represent meanϮSD (nϭ5). *PϽ0.05. may be involved in this process, but the exact mechanism remains unclear. DN-Ubc9 and PIAS1 siRNA impaired ERK5-SUMOylation suggesting the involvement of Ubc9 and PIAS1 in ERK5-SUMOylation. Recently, the involvement of PIAS1 phosphorylation on regulating downstream events has been reported. PIAS1 can act by selectively inhibiting the recruitment of NF-B/STAT1 to the endogenous gene products. IKK␣ is associated with PIAS1 and mediates the Ser 90 phosphorylation of PIAS1, which in turn is required for PIAS1 to block the promoter binding of p65. In this report, the importance of both Ser 90 phosphorylation and SUMO ligase activity of PIAS1 to repress transcriptional Figure 8 . MEK5 activation inhibited the exacerbation of LV dysfunction after MI in diabetic, but not in nondiabetic mice. A, Kaplan-Meier survival analysis in nondiabetic NLC and CA-MEK5␣-Tg after MI. Survival rate in NLC (nϭ17) and CA-MEK5␣-Tg (nϭ18) mice after MI were plotted. There was no significant difference between these 2 groups in the nondiabetic condition. B, Kaplan-Meier survival analysis in diabetic NLC and CA-MEK5␣-Tg after MI. Survival rate in NLC (nϭ44) and CA-MEK5␣-Tg (nϭ41) mice after MI were plotted. Overall survival was significantly higher in CA-MEK5␣-Tg compared with NLC mice. *PϽ0.05 compared with the NLC group. C, Random blood sugar (BS) and body weight 1 week after injection of STZ with coronary ligation (DMϩMI) or vehicle injection with sham operation groups in NLC or CA-MEK5␣-Tg mice as indicated. D, LV weight/tibial length (TL) and lung weight/TL in STZ-treated coronary ligation (DMϩMI) or vehicle-treated sham operation groups in NLC or CA-MEK5␣-Tg mice 1 week after surgery as indicated. E, Echocardiographic data obtained from STZ-treated coronary ligation (DMϩMI), vehicle-treated coronary ligation (MI), or vehicletreated sham operation groups in NLC or CA-MEK5␣-Tg mice 1 week after surgery as indicated. LVEDd indicates left ventricle end-diastolic dimension; LVESd, left ventricle end-systolic dimension; TL, Tibial length. F, Hemodynamic measurements in STZ-treated coronary ligation (DMϩMI) or vehicle-treated sham operation groups in NLC or CA-MEK5␣-Tg mice 1 week after surgery as indicated. All data are expressed as meanϮSD. **PϽ0.01, *PϽ0.05. nϭnumber of the animals.
